Showing results (61-70 of 205) with videos related to

Sort By:
Pageof 21
Leukemia Research|October 7, 2009
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinibRonald L Paquette, John Nicoll, Meenal Chalukya, et al.
Cancer Research|March 12, 2009
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformationsMarkus A Seeliger, Pratistha Ranjitkar, Corynn Kasap, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2002
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loopSergei Roumiantsev, Neil P Shah, Mercedes E Gorre, et al.
European Journal of Medicinal Chemistry|December 6, 2023
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691LXiuqi Wang, Rosa Anna DeFilippis, Tsigereda Weldemichael, et al.
The Journal of Clinical Investigation|August 22, 2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyNeil P Shah, Brian J Skaggs, Susan Branford, et al.
Cancer Genetics|August 30, 2011
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitorsRonald L Paquette, John Nicoll, Meenal Chalukya, et al.
Pacing and Clinical Electrophysiology : PACE|March 11, 2004
Evaluation of safety and efficacy of pacemaker and defibrillator implantation by axillary incision in pediatric patientsJoselyn C R Lee, Kevin Shannon, Noel G Boyle, et al.
Urologic Oncology|December 3, 2014
Regulation of biologic oncology products in the FDA׳s Center for Biologics Evaluation and ResearchPeter F Bross, Chaohong Fan, Bindu George, et al.
American Journal of Hematology|August 19, 2015
Clinical features of pulmonary arterial hypertension in patients receiving dasatinibNeil P Shah, Nicola Wallis, Harrison W Farber, et al.
Blood|February 23, 2013
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDCatherine C Smith, Elisabeth A Lasater, Xiaotian Zhu, et al.
Pageof 21